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Modeling of the Sedative and Airway Obstruction Effects of
Propofol in Patients with Parkinson Disease undergoing
Stereotactic Surgery
Neus Fábregas, M.D.,* Javier Rapado, Pharm.D.,† Pedro L. Gambús, M.D.,‡ Ricard Valero, M.D.,* Enrique Carrero, M.D.,‡
Lydia Salvador, M.D.,‡ Miguel A. Nalda-Felipe, M.D.,§ Iñaki F. Trocóniz, Ph.D.
Background: Functional stereotactic surgery requires careful
titration of sedation since patients with Parkinson disease need
to be rapidly awakened for testing. This study reports a popu-
lation pharmacodynamic model of propofol sedation and air-
way obstruction in the Parkinson disease population.
Methods: Twenty-one patients with advanced Parkinson dis-
ease undergoing functional stereotactic surgery were included
in the study and received propofol via target-controlled infu-
sion to achieve an initial steady state concentration of 1 g/ml.
Sedation was measured using the Ramsay Sedation Scale. Air-
way obstruction was measured using a four-category score.
Blood samples were drawn for propofol measurement. Individ-
ual pharmacokinetic profiles were constructed nonparametri-
cally using linear interpolation. Time course of sedation and
respiratory effects were described with population pharmaco-
dynamic models using NONMEM. The probability (P) of a given
level of sedation or airway obstruction was related to the esti-
mated effect-site concentration of propofol (Ce) using a logistic
regression model.
Results: The concentrations predicted by the target-con-
trolled infusion system generally exceeded the measured con-
centrations. The estimates of C50 for Ramsay scores 3, 4, and 5
were 0.1, 1.02, and 2.28 g/ml, respectively. For airway obstruc-
tion scores 2 and 3, the estimates of C50 were 0.32 and 2.98
g/ml, respectively. Estimates of ke0 were 0.24 and 0.5 1/min
for the sedation and respiratory effects, respectively.
Conclusions: The pharmacokinetic behavior of propofol in
patients with Parkinson disease differs with respect to the pop-
ulation from which the model used by the target-controlled
infusion device was developed. Based on the results from the
final models, a typical steady state plasma propofol concentra-
tion of 0.35 g/ml eliciting a sedation score of 3 with only
minimal, if any, airway obstruction has been defined as the
therapeutic target.
PARKINSON disease (PD) is a highly incapacitating pro-
cess affecting especially older populations.1 The ana-
tomic alteration is located in the neurons of the extra-
pyramidal system, and the main clinical manifestations
are rigidity and tremor.2 Besides these neurologic alter-
ations, respiratory dysfunction has been described in
these patients due to involuntary movements of the
glottis and supraglottic structures.3
Patients with PD resistant to pharmacologic treatment
may have the opportunity to undergo a therapeutic sur-
gical procedure in an advanced stage of their illness.
Stereotactic pallidotomy as well as the implantation of
electrodes to stimulate selected subthalamic regions can
be indicated to improve rigidity and tremor.4
Functional stereotactic surgery is performed with local
anesthesia, using computed tomography for the map-
ping of specific trigger points where electric stimulation
must be applied to achieve the therapeutic goals.5 Pa-
tients need sedation for this long and sometimes uncom-
fortable procedure, but they also need to awake rapidly
for electrocorticography or neuropsychiatric testing.
Since this is an intracranial surgical procedure, access to
the head and airway is very limited. In this setting,
respiratory depression can quickly become an emer-
gency, and thus sedation must be carefully titrated to
avoid oversedation with respiratory depression.
The pharmacokinetics of propofol are characterized by
a high hepatic extraction ratio and rapid distribution into
peripheral tissues. Plasma concentrations decay rapidly
after infusion termination.6–10 The pharmacodyamics of
propofol are characterized by a clear-headed emergence,
rapid return of orientation, and decreased incidence of
nausea and vomiting.11,12 These pharmacokinetic and
pharmacodynamic properties make propofol a suitable
anesthetic to be used in patients with PD undergoing
functional stereotactic surgery; however, the relation
between drug kinetics and depth of sedation in this type
of patients has not been characterized.
A constant level of sedation can be achieved by pro-
ducing a constant propofol concentration in the plasma
and biophase.13 Target controlled infusion (TCI) systems
have been used in clinical and experimental setting since
1981.14 TCI systems use specific pharmacokinetic mod-
els validated in appropriate populations.15–17 Such sys-
tems must account for identified pharmacokinetic and
pharmacodynamic covariates in the population of
interest.18
The goal of this study was to model the relation be-
tween plasma propofol concentration and sedation or
respiratory obstruction in patients with PD undergoing
functional stereotactic pallidotomy receiving propofol
with the TCI device Diprifusor® (Master TCI, Fresenius
Vial S.A., Brezins, France). The pharmacodynamic model
was then used to determine the therapeutic propofol
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concentration that would keep a patient with PD se-
dated without inducing dangerous airway obstruction.
As a secondary objective we characterized the perfor-
mance of the pharmacokinetic model used by the Dipri-
fusor® in this subpopulation of patients with PD.
Materials and Methods
After we obtained institutional review board approval
and written informed consent, 21 patients with PD
scheduled for stereotactic pallidotomy or implantation
of subthalamic nuclei electrodes were enrolled in the
study. Patient demographics are summarized in table 1
together with duration and total dose of propofol in-
fused during surgery. All patients were in an advanced
stage of a PD resistant to pharmacologic therapy. Prior to
surgery, several comedications were administered, all of
them related to PD treatment.
Patient Preparation
All patients were premedicated with 5 mg diazepam
administered orally 2 h before starting the surgery. A
stereotactic frame was positioned after infiltration of the
scalp with 0.5% bupivacaine. Afterward, cranial com-
puted tomography was performed. Once the patient
arrived in the operating room, a catheter was placed in
the radial artery for continuous monitoring of arterial
blood pressure and blood sampling. Other monitoring
systems included pulse oximetry, continuous expiratory
carbon dioxide monitoring, and electrocardiogram. Oxy-
gen administration (4 l/min) was provided through nasal
prongs. Urine output was measured hourly. Compres-
sion stockings were placed in the lower extremities to
help venous blood return.
Drug Administration, Blood Sampling, and
Pharmacodynamic Measurements
The target controlled infusion pump (TCI-Diprifusor®)
administered propofol (Diprivan®; AstraZeneca, Wil-
mington, DE) as required by the pharmacokinetic model
reported by Marsh et al.,16 which scales the size of
central volume of distribution to the body weight of the
patient. The Diprifusor® was programmed to rapidly
achieve a propofol plasma concentration of 1 g/ml in
2-min duration and then maintain it as required.19,20 It
was subsequently manually and empirically adjusted to
achieve adequate sedation.
Blood samples (7 ml) were drawn every 30 min from
the start of infusion, if at least 10 min had elapsed since
achieving every new target concentration, and also at 1,
2, 3, 4, 6, 8, 10, 15, and 20 min after the infusion was
stopped at the end of the surgery. Blood was collected in
heparinized tubes and centrifuged at 10,000 rpm for 15
min. Plasma (4.5 ml) was then transferred to polypro-
pylene tubes and stored at 20°C until assayed. Propofol
was extracted with percloric–acetonitrile (50:50) after
1 min of strong agitation. The upper phase (0.05 ml)
was analyzed using high-performance liquid chromatog-
raphy with ultraviolet detection at 251 nm. The mobile
phase consisted of acetonitrile, water, and acetic acid
(670:329.6:0.4). The limit of detection was 0.075 g/ml,
and the coefficient of variation of the assay was 4.12% for
concentrations from 0.1 to 5 g/ml.
Sedation was measured according to Ramsay Sedation
Scale.21 The degree of airway obstruction was measured
Table 1. Patient Demographics for the Current Study
Patient
(n°)
Gender
(M/F)
Height
(cm)
Age
(yr)
Weight
(kg)
Duration
(h)
Total Dose
(mg)
1 M 165 75 65 6.88 1213
2 M 170 43 70 9.41 1260
3 M 156 64 60 5.21 507
4 F 155 67 72 9.60 1082
5 M 167 59 75 5.55 792
6 M 155 56 103 6.45 1402
7 F 150 61 62 5.12 702
8 M 168 75 60 10.10 1357
9 M 165 66 61 10.12 2472
10 F 155 68 83 6.72 943
11 M 175 65 70 6.48 663
12 F 155 49 85 9.18 1016
13 F 148 71 45 8.72 322
14 M 155 61 80 8.15 604
15 F 162 62 60 7.98 1192
16 M 149 67 70 0.99 282
17 F 158 70 59 7.05 480
18 F 160 64 72 9.04 1035
19 M 162 69 60 6.93 443
20 M 171 46 74 9.53 752
21 M 170 65 65 4.47 671
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according to a four-category scale (table 2). Sedation and
airway obstruction measurements were performed and
recorded 10 min after each new propofol target level
was achieved to ensure that a steady state propofol
effect-site concentration was achieved.
Data Analysis
Pharmacokinetics. The TCI system generated com-
plete records of the infusion rate and predicted plasma
and effect-site concentrations of propofol at any time
during the study. Those data were used to prospectively
evaluate the performance of the model by comparing the
predictions with the actual plasma concentrations of
propofol at the times that propofol arterial blood sam-
ples were drawn.
To evaluate the predictive performance of the Diprifu-
sor® internal pharmacokinetic model, the median per-
formance error [MDPE (%)] and the median absolute
performance error (%), together with the 95% confi-
dence interval of MDPE (%) were computed and used to
represent bias and precision respectively. Performance
error [PE (%)] was calculated as:
PE%  Cobs  CpredCpred  100 (1)
where Cobs and Cpred represent the observed propofol
concentrations and the concentrations predicted by the
TCI device, respectively.22 If the 95% confidence inter-
vals of MDPE included the zero value, it was concluded
that no significant bias was present.
Pharmacodynamics. The probability (P) of a given
level of effect (sedation or airway obstruction) was re-
lated to plasma propofol concentrations using the fol-
lowing sigmoidal equation:
PijEffect m
Cij
i
Cij
i  C50,m,i
i (2)
where Pij (Effect  m) is the probability in the ith
individual at that the jth effect score would be equal to
or greater than (i.e., “deeper than”) a given discrete level
(m), Cij is the ith individual concentration of propofol in
plasma at jth observation, C50,m,i is the steady state
plasma concentration associated with 50% probability
corresponding to the ith patient, and i is the steepness
of the probability versus concentration curve corre-
sponding to the ith patient. Interindividual variability
was incorporated in the model as follows:
C50m,i  C50 pop,m  e
C50,m,i (3)
where C50,m,i represents the difference between the
typical (mean) population value of C50,m (C50,pop,m) and
the individual specific C50,m (C50,m,i). It is assumed that
C50,m is a random variable symmetrically distributed
around 0 with variance 	2C50,m. As implied by equation
3, C50,m has a log-normal distribution. During the model
development process, the significance of including dif-
ferent interindividual variability terms in C50 and  for
each of the sedation or airway obstruction scores was
evaluated.
The complete model for each of the two responses
studied consisted of three submodels, one for each of
the scores: 3, 4, and 5 for sedation and 2, 3, and 4 for
airway obstruction, respectively. Sedation score of 2 and
airway obstruction score of 1 were not modeled since
these are baseline scores when no concentration of
propofol was present.
Equation 2 does not predict an effect score directly,
but rather predicts the probability of being at or deeper
than a particular level. At any given concentration there
is a finite probability of being at a particular sedation or
airway obstruction score, the sum of those probabilities
for all possible scores necessarily being 1. The probabil-
ity of being at a particular score as a function of concen-
tration can be calculated as:
PijEffect m PijEffectm PijEffectm 1
(4)
Previous publications have applied the model shown
in equation 2 to propofol using effect site concentrations
(Ce) rather than plasma propofol concentrations.23,24
For this reason we tested a model similar to equation 2
but using Ceij. Since there was not a pharmacokinetic
model prior to the analysis of the pharmacodynamic
responses, the individual propofol plasma concentra-
tion-versus-time profiles were generated nonparametri-
cally using linear interpolation. This procedure allowed
us to obtain predicted values of Ceij through the estima-
tion of ke0,i, the first-order rate constant governing the
distribution from plasma to the biophase in the ith indi-
vidual,25 which was modeled as:
ke0,i  ke0,pop  e
ke0,i (5)
where ke0,i represents the difference between the typ-
ical (mean) population value of ke0, ke0pop, and the
individual specific ke0 (ke0,i). It is assumed that ke0 is a
random variable symmetrically distributed around 0 with
variance 	2ke0.
Table 2. Ramsay Sedation and Airway Obstruction Scores (and
their Clinical Meaning) used as Pharmacodynamic End-points
Ramsay Sedation Score Airway Obstruction Score
1. Anxious, agitated and
restless
1. Normal breathing
2. Cooperative, orientated, and
tranquil
2. Deep breathing
3. Response to command only 3. Snoring
4. Brisk response to stimuli 4. Severe airway obstruction
5. Sluggish response to stimuli —
6. No response —
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Table 1 shows five continuous and one categoric (gen-
der) covariates. The effect of these covariates on the
parameter estimates was also tested. For example, there
is the possibility that as the duration of the surgery
(DUR) increases, the potency of propofol decreases (i.e.,
C50,m increases); this phenomena was modeled as:
C50,m,i  C50,m,pop  1  
DUR  DURi  e
C50i
(6)
where 
DUR is the slope of the C50,m versus DUR curve.
All the population analyses were performed using the
Laplacian estimation method with the “likelihood” op-
tion as implemented in NONMEM version V.26 The re-
sults from the population analysis are presented as
model estimate, together with the relative standard er-
ror, computed as the ratio between the standard error of
the estimate and the value of the estimate.
Model Selection
A model was considered superior to another nested
model when the minimum value of the objective func-
tion (OBJF) was reduced by 3.88 points. The difference
in OBJF between two nested models is approximately
chi-square distributed and can be used for significance
tests (P  0.05, with 1 degree of freedom). For model
selection, the OBJF was used together with the visual
exploration of the goodness-of-fit plots.
When dealing with continuous variables (i.e., drug
concentrations in plasma) the most frequent graphical
representations are the observations versus model pre-
dictions, residuals versus predictions, etc. One of the
problems in analyzing categoric data such as sedation
and airway obstruction scores is that model predictions
are conditional probabilities of getting a certain score,
instead of the observed score itself. Therefore, residual
errors could not be calculated and residual plots, a stan-
dard analysis tool, could not be constructed.
To evaluate graphically the descriptive performance of
the selected population models, a model predictions
versus observations type goodness-of-fit plot was devel-
oped. The entire range of observed plasma concentra-
tions of propofol was divided in six intervals (0, 0 to
0.2, 0.2 to 0.4, 0.4 to 0.6, 0.6 to 1, and
1 g/ml). Those intervals were chosen in a way that
the number of observed scores within each interval was
high enough to compute reliable mean raw data proba-
bilities: 36, 74, 58, 49, 66, and 70 scores for sedation and
36, 75, 59, 49, 66, and 70 scores for airway obstruction,
respectively. For each of the concentration intervals, the
mean raw data and mean model predicted probabilities
of having a certain score “m” were computed, and the
goodness-of-fit plot was constructed plotting the mean
model predicted versus the mean raw data probabilities.
For each interval, mean raw data probabilities of having
a certain score “m” were calculated as the ratio between
the number of observed scores equal to the “m” score
and the total number of observed scores. To obtain
model predicted scores, 100 datasets were simulated
using the fixed and random effect parameters estimated
from the selected population model. Each of the simu-
lated datasets contained the same number of patients,
demographic characteristics, design history, and sam-
pling schedule as the original; in addition, the concen-
trations of propofol in plasma were also the same, since
individual pharmacokinetic profiles were created using
linear interpolation. Mean model predicted probabilities
of having a certain score “m” were then calculated as the
ratio between the number of simulated scores equal to
the “m” score and the total number of simulated scores.
Model Validation
Case deletion diagnostics or cross-validation was used
to detect influential individuals and to explore the ro-
bustness of the model.26 Cross-validation was performed
by refitting the selected model with one patient ex-
cluded; therefore, 21 different sets of population param-
eters were obtained, each of them estimated from 20
individuals. To summarize the results of the case dele-
tion diagnostics, MDPE (%), median absolute perfor-
mance error (%), and the 95% confidence interval of
MDPE (%) were computed. PE (%) in this case was
calculated as:
PE% 
Pest  PCD
PCD
 100 (7)
where Pest and PCD represent parameter (fixed or ran-
dom) estimates using the original and case deletion data-
sets, respectively.
Results
Pharmacokinetics
The mean duration of propofol infusion was 7.12 h
(range, 0.99–10.12 h). From a total of 355 plasma sam-
ples analyzed, 86 showed plasma concentrations of
propofol below the limit of quantification, and the range
of observed concentrations of propofol in plasma varied
from 0.08 to 2.58 g/ml.
Figure 1 shows the individual PE (%) versus time pro-
files based on the observed and TCI prediction data,
where it can be observed that the majority of the data
points lie below the line of zero PE (%) (line correspond-
ing to a perfect prediction). In this population of pa-
tients, the measured propofol concentrations were sys-
tematically overpredicted by the TCI device. It should be
noted that data with plasma concentrations of propofol
below the limit of quantification were not included in
the computation of PE (%).
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Pharmacodynamics
A total of 356 scores of sedation and 355 scores of
airway obstruction were recorded simultaneously to the
arterial blood samples. Two measures of sedation were
from a patient who was momentarily agitated (m  1)
and were therefore not included in the dataset. Sixteen
observations from six patients were from severe respira-
tory effects (m  4), but none of the patients in the study
were highly sedated (m  6).
Figure 2 shows the relation between the observed
concentrations of propofol in plasma and observed se-
dation and airway obstruction scores in all individuals.
An apparent relation between plasma propofol concen-
tration and effect can be observed. During the linear
interpolation process, as a part of the pharmacodynamic
analysis, concentrations below the limit of quantification
were included in the analysis with a fixed value equal to
half the detection limit of the assay (0.0375 g/ml).
Once the population pharmacodynamic model was se-
lected, the effect of this approach on parameter estima-
tion was evaluated by fitting the models to the data using
different fixed values for concentrations below the limit
of quantification, i.e., 1/1 of the limit of detection of the
assay, 1/4 of the limit of detection of the assay, and 1/8
of the limit of detection of the assay. The results re-
mained the same.
The time course of sedation and airway obstruction
effects were best described with an Emax model (, the
steepness of the probability vs. concentration curve, was
not significantly [P  0.05] different from 1) using the
effect-site concentrations of propofol as predictor vari-
able. Including the effect-site concentrations instead of
plasma propofol concentrations, the decrease in OBJF
was highly significant (38 and 25 points for sedation and
airway obstruction, respectively; P  0.001). Interpa-
tient variability associated with C50,m was found to be
highly significant (P  0.001); however, the data did not
support the estimation of different variance terms for
each C50,m as well as interindividual variability in  or
ke0. In addition, none of the individual characteristics
showed significant covariate effects (P  0.05). Table 3
Fig. 1. Individual prediction error versus time profiles. They are
computed from the set of parameters reported by Marsh et al.16
and used for the TCI system, and the observed propofol plasma
concentrations from the current study. The thick solid line
represents the 0% prediction error, and the thick dashed line
corresponds to a Loess smoother (S-PLUS 2000; Mathsoft Inc.,
Seattle, WA) through the data.
Fig. 2. Description of the raw data. Ramsay sedation scores (top)
and airway obstruction scores (bottom) versus observed plasma
propofol concentrations.
Table 3. Summary of the Results of the Final Population
Pharmacodynamic Models Selected for Sedation and Airway
Obstruction
Parameter Estimate [RSE]
Sedation
ke0 (1 min) 0.24 [0.35]
C50 (3) (g/ml) 0.10 [0.31]
C50 (4) (g/ml) 1.02 [0.28]
C50 (5) (g/ml) 2.28 [0.41]
Interindividual variability 1.36 [0.28]
Airway obstruction
ke0 (1/min) 0.50 [0.22]
C50 (2) (g/ml) 0.32 [0.45]
C50 (3) (g/ml) 2.98 [0.44]
Interindividual variability 3.50 [0.27]
ke0  first order rate constant describing the removal of the drug from the
effect site; C50(m)  steady-state propofol plasma concentration associated
with 50% probability of being at least at the “m” score. RSE  relative
standard error. See text for details.
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lists the final population parameter estimates obtained
for sedation and airway obstruction effects. It can be
observed that all sedation-related parameters were esti-
mated with adequate precision. The estimate of C50
corresponding to an airway obstruction score of 4 was
24 g/ml and was considered not reliable since 2.58
g/ml was the maximum propofol plasma concentration
achieved.
The graphic tool developed to evaluate the descriptive
model performance (fig. 3) and the results obtained from
the cross-validation shown in table 4 led to the conclu-
sion that the selected population models were sup-
ported by the observations.
Figure 3 shows the mean model predicted versus the
mean raw data probabilities of having a certain score
“m” for sedation and airway obstruction in each of the
predefined propofol concentration intervals. In both
parts of figure 3 the number of data pairs is 24, corre-
sponding to four scores (represented with different
symbols) for each of the six concentration intervals. In
addition, the number of observations equal to a cer-
tain score within each concentration interval has been
taken into account, making the size of the symbols
proportional to the square root of such number. It can
be observed that data pairs are randomly distributed
around the line of identity, and no trends are apparent
as a function of the score or number of observations in
the selected concentration intervals. This suggests
that the structure of the model selected was appropri-
ate and that no major model assumption violations
(i.e., nonsimmetrically distribution of C50 around 0)
are present.
The results of the case deletion diagnostics (table 4)
show that the population models selected are stable,
since none of the 21 individuals was found to be mark-
edly influential on any of the parameters estimated by
the models. This can be assessed by the absence of bias
and the high precision in the parameters. It is interesting
to note that the bias and precision values for ke0 were
similar to those obtained for the rest of parameters
because, due to the quantal nature of the responses and
the characteristics of the study design, one would ex-
pect a difficult description of the effect site distribution
properties. Additional checks, such as fixing the estimate
of ke0 to previously reported values,
18 were conducted
to further investigate this issue and showed significant
(P  0.05) increases in the OBJF values.
The probability curves for discrete levels of sedation
and airway obstruction are shown in figure 4. The steady
state plasma propofol concentrations corresponding to
the peak probabilities (i.e., probability modes) for seda-
tion scores of 3 and 4 were 0.35 and 1.55 g/ml, respec-
tively, and for airway obstruction scores of 2 and 3 were
0.75 and 8.5 g/ml, respectively. The curves corre-
sponding to sedation scores of 2 and 5 continuously
decrease and increase, respectively, as the propofol con-
centration increases; a similar pattern was observed for
airway obstruction scores. The profiles represented in
figure 4 show that for a typical steady state propofol
plasma concentration of 0.35 g/ml, the probability of
adequate level of sedation is maximal with a minimum
risk of severe airway obstruction.
Fig. 3. Mean model predicted versus mean raw data probabili-
ties of having a certain “m” score for sedation (top) and airway
obstruction (bottom). They are computed at specific intervals of
steady state plasma concentrations of propofol. The size of each
point is proportional to the square root of the number of ob-
servations used to compute the mean value. Solid lines repre-
sent the line of identity.
Table 4. Results of the Case Deletion Diagnostics
Parameter MDPE (%) 95%C.I. MDAPE (%)
Sedation
ke0 4.08 -8, 1 6.32
C50 (3) 5.71 -2, 9 7.30
C50 (4) 0.68 -1, 3 5.77
C50 (5) 0.82 -2, 3 8.09
Interindividual variability 0.26 -3, 2 5.36
Airway Obstruction
ke0 10.91 -37, 59 11.96
C50 (2) 3.98 -27, 19 8.07
C50 (3) 0.70 -21, 19 7.55
Interindividual variability 5.14 -18, 28 7.88
ke0  first order rate constant describing the removal of drug from the effect
site; C50 (m)  steady-state propofol plasma concentration associated with
50% probability of being at least at the 	m	 score; C.I.  confidence interval;
MDPE  median of the predicted errors; MDAPE  median of the absolute
predicted errors.
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Discussion
In the current study, a population pharmacodynamic
model of sedation and airway obstruction effects, during
TCI propofol infusions in patients with PD undergoing
stereotactic pallidotomy or implantation of subthalamic
nuclei electrodes, is presented. A better understanding
of this relation should help clinicians to achieve desired
sedation levels without major airway obstruction prob-
lems when dealing with this patient population.
A TCI system was used to achieve plasma target propo-
fol concentrations of 1 g/ml. Sedation and airway ob-
struction effects were measured and modeled as phar-
macodynamic variables. Both scoring systems have been
used previously by several investigators20,27; however, to
date, modeling of these effects in PD populations has not
been yet performed. Elderly patients are more sensitive
to the hypnotic and electroencephalogram measure-
ments of propofol than younger individuals18 and pa-
tients with certain central nervous system dysfunctions
such as PD. Developing safe pharmacologically based
sedation schemes can help provide better care to pa-
tients with PD.
The TCI system used in the current study implemented
the pharmacokinetic model proposed by Marsh et al.16
and resulted in a significant overprediction of the ob-
served plasma propofol concentrations. The differences
between predicted and observed values could be a result
of differences in weight and age found between the two
patient populations. The pharmacokinetic profile of
propofol seems to be influenced not only by weight, but
also by age, height, and lean body mass when it is used
as the only anesthetic agent.27 Differences in the infu-
sion duration and range of concentrations targeted could
also be important,27 since it has been suggested that
blood clearance of propofol may decrease in long infu-
sions because of a decrease of liver perfusion. Another
possibility could be that propofol exhibits different phar-
macokinetic characteristics in patients with PD, perhaps
because of the concomitant antiparkinsonian medica-
tion; however, no data are available on this point. In
addition, all of the patients in the population studied by
Marsh et al.16 received alfentanil; however, such opioid
was not used in the current study.
No attempts to model the pharmacokinetic profile
were conducted since the design was not adequate for a
kinetic study of a drug such as propofol, characterized
by a fast distribution and a three-compartment model
behavior. The pharmacodynamic analysis was compli-
cated by several problems with the study design. First,
the Ramsay scale used to assess sedation has limitations.
As an ordered categoric scale, a sedation score of 2
represents a deeper sedation level than a sedation score
of 1. However, 1 represents agitation, whereas 2 repre-
sents calm, presumably the baseline. There is no provi-
sion in the Ramsay scale for a patient who is sedated yet
agitated, although such patients are not uncommon. In
addition, a sedation score of 2 may be the true baseline
for no drug effect, whereas there were several records in
the dataset corresponding to patients with high propofol
concentrations who had a sedation score of 2. A second
complication is that mental status naturally changes in
the absence of drugs. Most persons alternate from a level
of 2 (awake) to 3 (sedated) and 4 (asleep) during the day,
especially in long surgical procedures such as the one
reported here. It is obvious that the level of sedation is
not entirely a function of plasma concentration, as rep-
resented in our final pharmacodynamic model. The third
and most important limitation of our study is that, be-
cause it was conducted in patients during the actual
surgical procedure, it was not possible to increase the
target levels of propofol without jeopardizing the condi-
tion of the patient, as the attendant anesthesiologist had
no easy access to the head and the airway of the patient.
That is why the design did not explore deep sedation
(m  6) or severe airway obstruction scores (m  4).
Although these were not explored, the study design did
permit us to identify a clinically optimal range for seda-
tion without compromising a clear airway structure.
The most popular model used to describe the time
course of the drug effect after propofol administration is
the effect compartment model.25 This model has been
previously applied to electroencephalograms28,29 and
Fig. 4. Probability curves for discrete sedation (top) and airway
obstruction (bottom) scores. The peak probability (modes) for
each curve corresponds to the steady state plasma concentra-
tion of propofol at which a discrete level of response is most
likely to occur.
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was also selected in both pharmacodynamic responses
studied in the current study. The estimate of ke0 for
sedation was half the value obtained for airway obstruc-
tion (0.24 and 0.50 1/min, respectively) and in the range
of the values reported previously by Schnider et al.
(0.456 1/min).18 The final models were rerun fixing the
value of ke0 to the value reported by Schnider et al. For
the case of the sedation, minor changes in the OBJF and
parameter estimates were found; however, for respira-
tory depression, a significant increase in the value of
OBJF was seen. This is relevant since Struys et al.30
compared different values of ke0 when using a TCI sys-
tem to target effect site propofol concentration. Their
study demonstrated that the value of ke0 reported by
Schnider et al. was the one whose time course of effect-
site concentration paralleled the best with the actual
time course of effect, measured by means of the Bispec-
tral Index of the processed electroencephalogram in
most patients.
The estimates obtained for C50 were 0.10, 1.02, and
2.28 g/ml for sedation levels of 3, 4, and 5, assuming
level 2 as baseline. The estimates of C50 reported previ-
ously in the literature varied as a function of the phar-
macodynamic endpoints studied; values of 0.31 g/ml
were estimated for the ability of propofol to prevent
postoperative nausea and vomiting,31 and a higher C50
of 1.38 g/ml was found for the electroencephalogram
effects.18 The value reported by Wakeling et al.13 of
4.5 g/ml when loss of consciousness was explored
could be compared with the concentrations needed in
the current study to achieve a score of 6 in the Ramsay
scale. However, this value of the scale was not reached
during the surgical procedure; therefore, the probability
could not be modeled. The estimates of C50 for a seda-
tion score of 5 and an airway obstruction score of 3 are
close to the maximum observed propofol plasma con-
centration; however, we think that the data support
those estimates because two of the three parameters of
the model are a priori known: E0  0 and EMAX  1. To
further explore this issue, a reparameterized form of the
EMAX model, proposed for those cases where observed
concentrations elicit effects far from EMAX,
32 was also
fitted to the data, and the derived C50 estimates were
identical to those reported in table 3.
Barr et al.33 correlated propofol concentrations to se-
dation scores, but in mechanically ventilated patients in
the intensive care unit. The values of C50 reported were
0.13, 0.5, 0.74, 1.48, and 2.34 g/ml for Ramsay sedation
scores of 2, 3, 4, 5, and 6, respectively. It must be
pointed out that, in addition to intubation and mechan-
ical ventilation, some of these patients were receiving
opioids as analgesics. Opioids can increase the sedative
properties of propofol or alter its pharmacokinetics. In-
tegrating results from the pharmacokinetic and pharma-
codynamic analyses, Barr et al.33 were able to develop
dosing regimens for propofol in patients in the intensive
care unit and described interesting features such as the
emergence time (i.e., time required for the level of se-
dation to decrease from 5 to 2). This type of information
could not be extracted from our results since no kinetic
model was proposed; therefore, the pharmacokinetics of
propofol in patients with PD with nonconcomitant ad-
ministration of opioids should be specifically addressed.
Because of the consistent overprediction of the model, it
can be said that the TCI system is safe for this population
in that it will not give the patients a higher plasma
concentration than what has been programmed.
In conclusion, a model relating propofol concentration
and sedation and airway obstruction has been developed
and validated for patients with PD undergoing stereotac-
tic and electrode implantation surgery. Based on the
results from the final models, a typical steady state
plasma propofol concentration of 0.35 g/ml, eliciting a
sedation score of 3 with only minimal, if any, airway
obstruction, has been defined as the therapeutic target.
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